Research Progress on Intracranial Lymphatic Circulation and Its Involvement in Disorders

Abstract

The lymphatic system is an important part of the circulatory system, as an auxiliary system of the vein, which has the functions of immune defense, maintaining the stability of the internal environment, and regulating the pressure of the tissue. It has long been thought that there are no typical lymphatic vessels consisting of endothelial cells in the central nervous system (CNS). In recent years, studies have confirmed the presence of lymphatic vessels lined with endothelial cells in the meninges. The periventricular meninges of the CNS host different populations of immune cells that affect the immune response associated with the CNS, and the continuous drainage of interstitial and cerebrospinal fluid produced in the CNS also proceeds mainly by the lymphatic system. This fluid process mobilizes to a large extent the transfer of antigens produced by the CNS to the meningeal immune cells and subsequently to the peripheral immune system through the lymphatic network, with clinically important implications for infectious diseases, autoimmunity, and tumor immunology. In our review, we discussed recent research advances in intracranial lymphatic circulation and the pathogenesis of its associated diseases, especially the discovery of meningeal lymphatic vessels, which has led to new therapeutic targets for the treatment of diseases associated with the intracranial lymphatic system.

The Potential Value of m6A RNA Methylation in the Development of Cancers Focus on Malignant Glioma

“…WTAP has also been shown to be upregulated in AML cells and to play an essential role in the abnormal proliferation and inhibition of differentiation of leukemic cells ( 130 ). METTL14 was highly expressed in AML cells carrying t(11q23), t ( 15 , 17 ) or t(8;21) translocations and was downregulated during myeloid differentiation ( 131 ). Knockdown of METTL14 facilitated AML and normal HSPC cells’ myeloid terminal differentiation and suppressed the proliferation of AML cells.…”

“…Despite the use of comprehensive therapies such as surgery, radiotherapy, and novel immunotherapies, the 2-year survival rate for GBM is only 15 months, and reliable biomarkers and effective immunotherapy targets for GBM are still lacking ( 6 , 14 ). Patients with GBM present a complex state of immune dysfunction involving several mechanisms of immunosuppression and tolerance, and immunotherapy has emerged as a novel approach to GBM treatment ( 6 , 15 ). Studies have demonstrated that GBM is more heterogeneous than peripheral tumors, which indicates that several factors including RNA modification, tumor microenvironment (TME), and stem cell phenotype may influence immune checkpoint blockade therapy and developmental plasticity in GBM ( 16 ).…”